Abstract
This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature has been extracted for new evidence from randomized controlled trials, open treatment studies and reported expert opinion, both in original articles and reviews, and evaluates indications and safety issues based on published data. After data extraction from published full length publications and critically weighing the evidence and potential impact of the data, the review has been drafted and circulated within the National MS Societies and the European MS Platform to reach consensus within a very large group of European experts, combining evidence-based criteria and expert opinion where evidence is still incomplete. The review also outlines a few areas of controversy and delineates the need for future research.
Similar content being viewed by others
References
MSTCG, et al. (2004) Escalating immunotherapy of multiple sclerosis – New aspects and practical application. J Neurol 251:1329–1339
MSTCG, et al. (2006) Symptomatic Treatment of Multiple Sclerosis. Eur Neurol 56:78–105
Goodin D, Frohman EM, Garmany GP Jr, et al. (2002) Disease modifying therapies in multiple sclerosis – Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS counsel for clinical practice guidelines. Neurology 58:169–178
McDonald W, Compston A, Edan G, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
Dalton C, Dalton CM, Brex PA, et al. (2002) Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52:47–53
Tintore M, Rovira A, Río J, et al. (2003) New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60:27–30
Polman CH, Wolinsky JS, Reingold SC (2005) Multiple sclerosis diagnostic criteria: three years later. Mult Scler 11:5–12
Polman CH, Reingold SC, Edan G, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846
Wiendl H, Kieseier BC, Gold R, et al. (2006) Revision der neuen McDonalds Kriterien zur Diagnose einer MS. Nervenarzt 77:1237–1245
Berger T, Rubner P, Schautzer F, et al. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139–145
Gaertner S, de Graaf KL, Greve B, Weissert R (2004) Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 63:2381–2383
Lampasona V, Franciotta D, Furlan R, et al. (2004) Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62:2092–2094
Rauer S, Euler B, Reindl M, Berger T (2006) Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 77:739–742
Kuhle J, Lindberg RL, Regeniter A, et al. (2007) Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 356:371–378
Lim ET, Berger T, Reindl M, et al. (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 11:492–494
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112
Nakashima I, Fujihara K, Sato S, Itoyama Y (2006) Clinical and MRI features of Japanese MS patients with NMO-IgG. J Neurol Neurosurg Psychiatry 77:1073–1075
Paul F, Jarius S, Aktas O, et al. (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4:e133
Matsuoka T, Matsushita T, Kawano Y, et al. (2007) Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130:1206–1223
Lucchinetti CF, Mandler RN, McGavern D, et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461
Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L (2001) Visual and motor evoked potentials in the course of multiple sclerosis. Brain 124:2162–2168
Kallmann BA, Fackelmann S, Toyka KV, Rieckmann P, Reiners K (2006) Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 12:58–65
Kappos L, Polman CH, Freedman MS, et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249
Anonymus (2006) Europäische Kommission genehmigt Aktualisierung der therapeutischen Indication für Rebif® www.serono.com/content/media/downloads/2006/20060710_de.pdf
Kappos L, Freedman MS, Polman CH, et al. (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370:389–397
Rio J, Tintoré M, Nos C, et al. (2005) Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 252:795–800
Kinkel RP, Kollman C, O’Connor P, et al. (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66:678–684
Pohl D, Rostasy K, Gärtner J, Hanefeld F (2005) Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 64:888–890
Ghezzi A, Amato MP, Capobianco M, et al. (2005) Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 11:420–424
Tenembaum SN, Segura MJ (2006) Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 67:511–513
Banwell B, Reder AT, Krupp L, et al. (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66:472–476
Sandberg-Wollheim M, Frank D, Goodwin TM, et al. (2005) Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 65:802–806
Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G (2005) The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 65:807–811
Clanet M, Radue EW, Kappos L, et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507–1517
Clanet M, Kappos L, Hartung HP, et al. (2004) Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 10:139–144
Freedman MS, Francis GS, Sanders EA, et al. (2005) Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 11:41–45
Vartanian T (2003) An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther 25:105–118
Panitch H, Goodin DS, Francis G, et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496–1506
Panitch H, Goodin D, Francis G, et al. (2005) Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 239:67–74
Schwid SR, Thorpe J, Sharief M, et al. (2005) Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 62:785–792
Durelli L, Verdun E, Barbero P, et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453–1460
Koch-Henriksen N, Sørensen PS, Christensen T, et al. (2006) A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66:1056–1060
Bertolotto A (2004) Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 17:241–36
Sorensen P, Koch-Henriksen N, Ross C, et al. (2005) Appearance and disappearance of neutralizing antibodies during interferon beta therapy. Neurology 65:33–39
Sorensen PS, et al. (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184–1191
Sorensen PS, Ross C, Clemmesen KM, et al. (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12:817–827
Polman C, Kappos L, White R, et al. (2003) Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60:37–43
Francis GS, Rice GP, Alsop JC (2005) Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65:48–55
Kappos L, Clanet M, Sandberg-Wollheim M, et al. (2005) Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65:40–47
Koch M, Mostert JP, de Vries JJ, De Keyser J (2007) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 68:1163–1164
Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP (2005) Immune response to immunotherapy: the role of neutralizing antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 4:403–412
Khan O, Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP, et al. (2001) A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing – remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 7:349–353
Haas J, Firzlaff M (2005) Twenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 12:425–431
Vallittu AM, Peltoniemi J, Elovaara I, et al. (2005) The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand 112:234–237
Flechter S, Vardi J, Pollak L, Rabey JM (2002) Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 197:51–55
Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M; 9006 Study Group (2007) Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology 68:939–944
Ramtahal J, Jacob A, Das K, Boggild M (2006) Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 253:1160–1164
Ziemssen T (2004) Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. Adv Exp Med Biol 541:111–134
Aharoni R, Eilam R, Domev H, et al. (2005) The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 102:19045–19050
Khan O, Shen Y, Caon C, et al. (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11:646–651
Wolinsky JS, Narayana PA, O’Connor P, et al. (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61:14–24
Filippi M, Wolinsky JS, Comi G (2006) Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 5:213–220
Simmons DL (2005) Anti-adhesion therapies. Curr Opin Pharmacol 5:398–404
Ropper AH (2006) Selective treatment of multiple sclerosis. N Engl J Med 354:965–967
Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:63–66
Theien BE, Vanderlugt CL, Eagar T, et al. (2001) Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 107:995–1006
Miller D, Khan OA, Sheremata WA, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23
Rudick RA, Stuart WH, Calabresi PA, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923
Polman CH, O’Connor PW, Havrdova E, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910
Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8:1275
Yousry TA, Major EO, Ryschkewitsch C, et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933
Khalili K, White MK (2006) Human demyelinating disease and the polyomavirus JCV. Mult Scler 12:133–142
Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358:647–648
BI GmbH BI (2008) http://www.biogenidec.com/site/products-on-the-market.html
European Medicines Agency (EMEA) (2008) EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/humandocs/Humans/EPAR/tysabri/tysabri.htm
Ghalie R, Edan G, Laurent M, et al. (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59:909–913
Ghalie R, RG, Mauch E, Edan G, et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8:441–445
Cocco E, Marchi P, Sardu C, et al. (2007) Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 13:975–980
Scott LJ, Figgitt DP (2004) Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18:379–396
Kappos L, Bates D, Hartung HP, et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431–441
Gold R, Jawad A, Miller DH, et al. (2007) Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 187:156–158
O’Connor PW, Goodman A, Willmer-Hulme AJ, et al. (2004) Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62:2038–2043
O’Connor PW, Li D, Freedman MS, et al. (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894–900
Kappos L, Antel J, Comi G, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124–1140
Sipe JC (2005) Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 5:721–727
Rose JW, Burns JB, Bjorklund J, et al. (2007) Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69:785–789
Bielekova B, Richert N, Howard T, et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Nat Acad Sci USA 101:8705–8708
Rose JW, Watt HE, White AT, Carlson NG (2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56:864–867
Hauser SL, Waubant E, Arnold DL, et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688
Bar-Or A, Calabresi PA, Arnold D, et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395–400
Coles AJ, Cox A, Le Page E, et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98–108
Coles AJ, et al. (2007) Efficacy of Alemtuzumab in Treatment-Naive Relapsing-Remitting Multiple Sclerosis: Analysis after Two Years of Study CAMMS223 Neurology (Suppl 1) 68:A100
Hirst CL, Pace A, Pickersgill TP, et al. (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 255:231–238
Markovic-Plese S, Bielekova B, Kadom N, et al. (2003) Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 60:1849–1851
Pulicken M, Bash CN, Costello K, et al. (2005) Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler 11:169–174
Calabresi PA, Wilterdink JL, Rogg JM, et al. (2002) An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58:314–317
Jeffery DR (2004) Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 63(Suppl 6):S41–S46
Smith DR, Weinstock-Guttman B, Cohen JA, et al. (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 11:573–582
Jeffery DR, Chepuri N, Durden D, Burdette J (2005) A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 11:296–301
Perini P, Calabrese M, Tiberio M, et al. (2006) Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: A comparative study. J Neurol 253:1034–1040
Sorensen PS (2003) Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials. Neurol Sci 24(Suppl 4):S227–S230
Achiron A, Kishner I, Sarova-Pinhas I, et al. (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515–1520
Hommes OR, Sørensen PS, Fazekas F, et al. (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149–1156
Sorensen PS, Haas J, Sellebjerg F, et al. (2004) IV immunoglobulins as addon treatment to methylprednisolone for acute relapses in MS. Neurology 63:2028–2033
Stangel M, Gold R (2005) Intravenous Immunoglobulins in MS. Int MS J 12:5–10,4
Haas J, Hommes OR (2007) A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 13:900–908
Achiron A, Kishner I, Dolev M, et al. (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251:1133–1137
Haas J (2000) High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 6(Suppl 2):S18–S20 and S33
Hartung H, Gonsette R, König N, et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. The Lancet 360:2018–2025
Krapf H, Morrissey SP, Zenker O, et al. (2005) Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 65:690–695
Avasarala JR, Cross AH, Clifford DB, et al. (2003) Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 9:59–62
Paul F, Dörr J, Würfel J, Vogel HP, Zipp F (2007) Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78:198–200
Edan G, Miller D, Clanet M, et al. (1997) Therapeutic effect of mitoxantrone combined with methylsprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118
Le Page E, Leray E, Taurin G, et al. (2008) Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 79:52–56
Confavreux C, Saddier P, Grimaud J, et al. (1996) Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46:1607–1612
Massacesi L, Parigi A, Barilaro A, et al. (2005) Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 62:1843–1847
Vermersch P, Stojkovic T, de Seze J (2005) Mycophenolate mofetil and neurological diseases. Lupus 14 (Suppl 1):S42–S45
Frohman EM, Brannon K, Racke MK, Hawker K (2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 27:80–83
Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN (2006) Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66:1245–1247
Vollmer T, et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607–1608
Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R (2004) Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 63:1081–1083
Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC (2006) Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 63:930–935
Comi G, Martino G (2006) MS treatment: New perspectives. Clin Neurol Neurosurg 108:339–345
Tomassini V, Paolillo A, Russo P, et al. (2006) Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253:287–293
Filippi M, Rocca MA, Arnold DL, et al. (2006) EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 13:313–325
Author information
Authors and Affiliations
Consortia
Corresponding authors
Additional information
Appendix
Multiple Sclerosis Therapy Consensus Group (MSTCG)
Austria. U. Baumhackl (St. Pölten), T. Berger (Innsbruck), F. Deisenhammer (Innsbruck), F. Fazekas (Graz), M. Freimüller (Hermagor), H. Kollegger (Vienna), W. Kristoferitsch (Vienna), H. Lassmann (Vienna), H. Markut (Vöcklabruck), S. Strasser-Fuchs (Graz), K. Vass (Vienna).
Belgium. C. Sindic (Brussels), M.B. D’hooghe (Melsbroek)
Croatia. S. Podobnik (Sarkanji)
Czech Republic. E. Havrdova (Prague)
Finland. I. Elovaara (Tampere)
France. M. Clanet (Toulouse), C. Confavreux (Lyon), G. Edan (Rennes), C, Lubetzki (Paris)
Germany. H. Altenkirch (Berlin), S. Bamborschke (Bernau), K. Baum (Hennigsdorf), A. Bayas (Augsburg), R. Benecke (Rostock), W. Brück (Göttingen), M. Buttmann (Würzburg), A. Chan (Bochum), M. Daumer (Munich), D. Dommasch (Bielefeld), W.G. Elias (Hamburg), E. Fasshauer (Halle), P. Flachenecker (Bad Wildbad), R. Gold (Bochum), J. Haas (Berlin), G. Haferkamp (Hanover), P. Haller (Osnabrück), H.-P. Hartung (Düsseldorf), C.Heesen (Hamburg), M. Heibel (Hachen), F. Heidenreich (Hannover), B. Hemmer (München), T. Henze (Niddenau), R. Hohlfeld (Munich), R. W. C. Janzen (Frankfurt/Main), G. Japp (Königstein), S. Jung (Dillingen), E. Jügelt (Sundern/Hachen), B. Kallmann (Bamberg), B. C. Kieseier (Düsseldorf), C. Kleinschnitz (Würzburg), J. Köhler (Hamburg), W. Köhler (Wermsdorf), W. Kölmel (Erfurt), N. König (Berg), G. Lehrieder (Bad Windsheim), V. Leussink (Düsseldorf), K. Lowitzsch (Ludwigshafen), M. Mäurer (Erlangen), U. Manegold (Göttingen), A. Melms (Tübingen), J. Mertin (Amtzell), S.G. Meuth (Würzburg), O. Neuhaus (Sigmaringen), P. Oschmann (Bayreuth), H.-F. Petereit (Cologne), M. Pette (Dresden), D. Pöhlau (Asbach), D. Pohl (Paris), P. Rieckmann (Würzburg/Vancouver), K. Ruprecht (Homburg), M. Sailer (Magdeburg), H. Schipper (Bernburg), S. Schmidt (Bonn), G. Schock (Gera), M. Schulz (Ueckermünde), S. Schwarz (Mannheim), G. Schwendemann (Bremen), D. Seidel (Isselburg), N. Sommer (Marburg/Göppingen), M. Stangel (Hannover), E. Stark (Offenbach), A. Steinbrecher (Regensburg), G. Stoll (Würzburg), K. V. Toyka (Würzburg), H. Tumani (Ulm), R. Voltz (Cologne), F. Weber (Munich), F. Weilbach (Bad Kissingen), H. Wiendl (Würzburg), H. Wiethölter (Stuttgart), B. Wildemann (Heidelberg), U. K. Zettl (Rostock), T. Ziemssen (Dresden), F. Zipp (Berlin), R. Zschenderlein (Berlin).
Greece. A. Orologas (Thessaloniki) Hungary. A. Guseo (Székesfehérvár)
Iceland. S. Bergmann (Reykjavik)
Italy. M. Pugliatti (Sassari)
Norway. K.-M. Myhr (Bergen)
Spain. G. Izquierdo (Sevilla),
Switzerland. C. Bassetti (Zurich), K. Beer (St. Gallen), S. Beer (Valens), U. Buettner (Aarau), M. Chofflon (Geneva), A. Gass (Basel/Mannheim), N. Goebels (Zurich), M. Götschi-Fuchs (Knoblisbühl), L. Kappos (Basel), J. Kesselring (Valens), H.-P. Ludin (St. Gallen), H. Mattle (Bern), M. Schluep (Lausanne), C. Vaney (Montana-Vermala).
U.K. D. Bates (Newcastle u. Tyne)
Rights and permissions
About this article
Cite this article
Multiple Sclerosis Therapy Consensus Group (MSTCG)., Wiendl, H., Toyka, K.V. et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. J Neurol 255, 1449–1463 (2008). https://doi.org/10.1007/s00415-008-0061-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-008-0061-1